Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy
Summary c-Met overexpression promotes tumor progression in many cancers, yet approved inhibitors benefit only patients with MET mutation, leaving most c-Met-overexpressing patients without effective therapy. Inspired by antibody-drug conjugates (ADCs), composed of an antibody linked to cytotoxic agents, a c-Met-targeti...